ArticleBJU international2023
Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
Article in BJU international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.BJU international · 2025Trial
- The divergence in new therapy options for patients undergoing bladder-sparing radiation versus cystectomy.Nature reviews. Urology · 2026Article
- INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.BJU international · 2026Article
- Article
- Multicentre real-world evaluation of the Haematuria Cancer Risk Score to risk-stratify the detection of bladder cancer in patients referred from primary care.BJUI compass · 2026Article
- Robotic segmental ureterectomy for upper tract urothelial carcinoma: comparable short-term oncological outcomes and improved postoperative recovery compared to open approach.World journal of surgical oncology · 2026Article
- Defining recurrent urinary tract infections and quantifying bladder cancer risk in primary care in England: a nationwide case-control study.The Lancet. Primary care · 2026Article
- Upper Urinary Tract Urothelial Carcinoma Diagnosis Effect on Life Expectancy Relative to Population-Based Controls: A Retrospective Analysis.Urologia internationalis · 2026Article
- Ward AdmiSsion of Haematuria: an Observational mUlticentre sTudy (WASHOUT) - study protocol.BMJ open · 2025Article
- Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness.PharmacoEconomics · 2025Article
- [Organ-preserving treatment for urothelial carcinoma of the upper urinary tract].Urologie (Heidelberg, Germany) · 2025Review
- Radiation-induced extracellular matrix remodelling drives prognosis and predicts radiotherapy response in muscle-invasive bladder cancer.Frontiers in oncology · 2025Article
- Single-cell and spatial transcriptomic analysis reveal cellular heterogeneity and cancer cell-intrinsic major histocompatibility complex II expression in urothelial carcinoma.International journal of biological sciences · 2025Article
- Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial.The journal of pathology. Clinical research · 2024Article
- Article
- Adjuvant immunotherapy for muscle-invasive urothelial carcinoma: Considerations for targeting patients.Bladder cancer (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveWe report NHS England data for patients with bladder cancer (BC), upper tract urothelial cancer (UTUC: renal pelvic and ureteric), and urethral cancers from 2013 to 2019. MATERIALS AND
methodsHospital episode statistics, waiting times, and cancer registrations were extracted from NHS Digital.
resultsRegistrations included 128 823 individuals with BC, 16 018 with UTUC, and 2533 with urethral cancer. In 2019, 150 816 persons were living with a diagnosis of BC, of whom 113 067 (75.0%) were men, 85 117 (56.5%) were aged >75 years, and 95 553 (91.7%) were Caucasian. Incidence rates were stable (32.7-34.3 for BC, 3.9-4.2 for UTUC and 0.6-0.7 for urethral cancer per 100 000 population). Most patients 52 097 (mean [range] 41.3% [40.7-42.0%]) were referred outside the 2-week-wait pathway and 15 340 (mean [range] 12.2% [11.7-12.6%]) presented as emergencies. Surgery, radiotherapy, chemotherapy, or multimodal treatment use varied with disease stage, patient factors and Cancer Alliance. Between 27% and 29% (n = 6616) of muscle-invasive BCs did not receive radical treatment. Survival rates reflected stage, grade, location, and tumour histology. Overall survival rates did not improve over time (relative change: 0.97, 95% confidence interval 0.97-0.97) at 2 years in contrast to other cancers.
conclusionThe diagnostic pathway for BC needs improvement. Increases in survival might be delivered through greater use of radical treatment. NHS Digital data offers a population-wide picture of this disease but does not allow individual outcomes to be matched with disease or patient features and key parameters can be missing or incomplete.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.